Back to Home

Companies in #Cardiovascular

Found 5 companies operating in this sector.

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. With Phase 3 data showing a 'potentially best-in-class profile,' Arrowhead plans to submit plozasiran for FDA approval by year-end to rival Ionis's Tryngolza in severe hypertriglyceridemia.

Sector:RNA Therapeutics
HQ:Pasadena, California, USA

Bristol Myers Squibb (NYSE: BMY) is a global biopharmaceutical company with a strong oncology franchise (Opdivo, Yervoy, Reblozyl, Pomalyst, Empliciti), hematology, cardiovascular (Eliquis), and immunology (Sotyktu, Zeposia, deucravacitinib). BMS is investing in cell therapy, radiopharmaceuticals, and next-generation immuno-oncology platforms.

Sector:Diversified Biopharmaceuticals
HQ:Princeton, New Jersey, USA

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures, and markets a broad range of generic, branded, and injectable pharmaceutical products. It is a leading supplier of sterile injectable medicines in the U.S. and operates one of the largest generics businesses in the MENA region.

Sector:Pharmaceutical / Generics and Injectables
HQ:London, United Kingdom (US operations: Berkeley Heights, NJ)

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. It is one of the largest pharmaceutical companies in the world, developing innovative medicines in therapeutic areas such as cardiovascular, renal, metabolic, immunology, neuroscience, and oncology.

Sector:Diversified Biopharmaceuticals
HQ:Basel, Switzerland

Hong Kong-listed (HKEX: 1177) pharmaceutical conglomerate specializing in biopharmaceuticals, modern Chinese medicine, and chemical medicines. Therapeutic focus on hepatobiliary, oncology, cardiovascular, and respiratory diseases.

Sector:Pharmaceutical
HQ:Hong Kong, China